Drugs / GD2-CAR-expressing Autologous T-lymphocytes
GD2-CAR-expressing Autologous T-lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04539366 | Jan 2022 → Dec 2040 | neuroblastoma, pediatric osteosarcoma | National Cancer Institute (NCI) | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GD2-CAR-expressing Autologous T-lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04539366 ↗ |
| Modality | Cell therapy | “an immune cell therapy called GD2CART” NCT04539366 ↗ |
| Route | Intravenous | “GD2CART cells IV” NCT04539366 ↗ |